

First Quarter FY 2027 Earnings Results

October 8, 2026

Forward looking statements



Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.



Leadership Transition


Eric Honroth named President and Chief Executive Officer, succeeding Jim Clemmer

- Eric Honroth appointed President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026, succeeding Jim Clemmer
- Follows a comprehensive Board-led search process
- Brings more than 20 years of leadership experience in medical devices and life sciences
- Proven track record of driving double-digit growth and profitability across large, global organizations
- Background spans cardiovascular, endovascular, urology, and oncology, directly aligned with AngioDynamics' markets
- Jim Clemmer to remain with the Company as an executive advisor

Q1 FY 2027 Key Takeaways



Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.



Continued Execution

- Net sales of \$80.9M, +6.9% YoY growth
- Med Tech segment sales of \$39.9M, +13.2% YoY growth
- Med Device segment sales of \$41.0M, +1.4% YoY growth

Focus on Profitability

- Adjusted EBITDA of \$5.0M


Balance Sheet Strength

- Ended quarter with \$34M in Cash
- Zero debt with flexibility of revolving line of credit
- Used ~\$15.3M of cash from operations in the quarter, in line with historical trends
- Will generate positive cash flow from operations in FY27


Q1 FY 2027 Financial Snapshot




Net Sales



Segment Revenue Contribution




Segment Gross Margin



Demonstrated Med Tech Growth Execution



Pro Forma Fiscal Year Net Sales (\$M)



Q1 FY 2027 MedTech Performance Snapshot



+13.2% growth driven by solid commercial execution and continued portfolio adoption

AURYON

Q1 FY 2027	Sales (\$M)	YoY Growth
Total Auryon	\$18.9	14.7%

ALPHAVAC

Q1 FY 2027	Sales (\$M)	YoY Growth
AlphaVac	\$4.5	37.4%
AngioVac	\$7.5	-5.9%

ANGIOVAC

Total Mech Thromb.	\$12.0	6.7%
Unifuse	\$0.7	-36.0%
Total Thrombus Mgmt.	\$12.7	3.0%

NANO KNIFE
Irreversible Electroporation (IRE) PROSTATE

Q1 FY 2027	Sales (\$M)	YoY Growth
Disposables	\$6.7	24.1%
Capital	\$1.7	53.5%
Total NanoKnife	\$8.3	29.0%

Key Highlights


- **Auryon:** Double-digit growth for the 21st straight quarter, driven by our hospital atherectomy shift, customer base expansion, and early international adoption.
- **Mechanical Thrombectomy:** Strong demand for AlphaVac and AngioVac, with continued progress on AlphaReturn and our infective endocarditis study, both IDE-approved.
- **NanoKnife:** Strong growth on record prostate volumes and probe demand, supported by expanding reimbursement coverage following last quarter's positive Medicare decision.

Fiscal Year 2027 Guidance

supported by balance sheet strength



Net Sales (\$M)



FY 2027 Financial Guidance*

Metric	Current Guidance
Net Sales	\$336.0M - \$341.0M
Med Tech Net Sales Growth	+12% - 15%
Med Device Net Sales Growth	Flat
Gross Margin	54% - 55%
Adjusted EBITDA	+\$13.0M - \$16.0M
Adjusted EPS	(\$0.29) - (\$0.24)



Appendix



Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss and Diluted Loss Per Share

(in thousands, except per share data)

	Three Months Ended	
	Aug 31, 2026	Aug 31, 2025
	(unaudited)	(unaudited)
Net loss	\$ (7,097)	\$ (10,903)
Amortization of intangibles	2,729	2,653
Acquisition, restructuring and other items, net ⁽¹⁾	2,181	2,758
Tax effect of non-GAAP items ⁽²⁾	350	1,313
Adjusted net loss	<u>\$ (1,837)</u>	<u>\$ (4,179)</u>
	Three Months Ended	
	Aug 31, 2026	Aug 31, 2025
	(unaudited)	(unaudited)
Diluted loss per share	\$ (0.17)	\$ (0.26)
Amortization of intangibles	0.06	0.06
Acquisition, restructuring and other items, net ⁽¹⁾	0.05	0.07
Tax effect of non-GAAP items ⁽²⁾	0.02	0.03
Adjusted diluted loss per share	<u>\$ (0.04)</u>	<u>\$ (0.10)</u>
Adjusted diluted sharecount ⁽³⁾	42,022	41,174

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended August 31, 2026 and 2025.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

Reconciliation of Net Loss to Adjusted EBITDA

(in thousands)

	Three Months Ended	
	Aug 31, 2026	Aug 31, 2025
	(unaudited)	(unaudited)
Net loss	\$ (7,097)	\$ (10,903)
Income tax (benefit) expense	(199)	65
Interest expense, net	88	4
Depreciation and amortization	5,498	5,950
Stock based compensation	4,502	4,470
Acquisition, restructuring and other items, net ⁽¹⁾	2,181	2,574
Adjusted EBITDA	<u>\$ 4,973</u>	<u>\$ 2,160</u>

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Detail of “Acquisition, Restructuring and Other Items, net”

(in thousands)



	Three Months Ended	
	Aug 31, 2026	Aug 31, 2025
	(unaudited)	(unaudited)
Legal ⁽¹⁾	\$ 406	\$ 213
Plant closure ⁽²⁾	617	2,345
Transition service agreement ⁽³⁾	—	(302)
CEO transition ⁽⁴⁾	770	—
Other	388	502
Total	<u>\$ 2,181</u>	<u>\$ 2,758</u>

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(3) Transition services agreements that were entered into with Merit and Spectrum.

(4) CEO retirement and transition expenses related to the CEO search and retention agreements with the Company's executive leadership team.